Oncorus Inc. (ONCR): Price and Financial Metrics


Oncorus Inc. (ONCR): $1.29

0.09 (+7.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ONCR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ONCR Stock Price Chart Interactive Chart >

Price chart for ONCR

ONCR Price/Volume Stats

Current price $1.29 52-week high $17.79
Prev. close $1.20 52-week low $1.03
Day low $1.20 Volume 52,200
Day high $1.30 Avg. volume 127,014
50-day MA $1.49 Dividend yield N/A
200-day MA $5.79 Market Cap 33.39M

Oncorus Inc. (ONCR) Company Bio


Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.


ONCR Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCR Latest Social Stream


Loading social stream, please wait...

View Full ONCR Social Stream

Latest ONCR News From Around the Web

Below are the latest news stories about Oncorus Inc that investors may wish to consider to help them evaluate ONCR as an investment opportunity.

Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing beginning Monday, January 10, 2022 at 7:00am ET under the Investors & Media

Yahoo | January 3, 2022

Head to Head Contrast: Kronos Bio (NASDAQ:KRON) versus Oncorus (NASDAQ:ONCR)

Oncorus (NASDAQ:ONCR) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 79.6% of Oncorus shares are held by institutional investors. Comparatively, 68.3% of []

Dakota Financial News | December 12, 2021

Oncorus, Inc. (NASDAQ:ONCR) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in shares of Oncorus, Inc. (NASDAQ:ONCR) by 43.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,493 shares of the companys stock after acquiring an additional 25,477 shares during the period. Charles Schwab Investment Management [] The post Oncorus, Inc. (NASDAQ:ONCR) Shares Purchased by Charles Schwab Investment Management Inc. appeared first on ETF Daily News .

ETF Daily News | November 29, 2021

One Oncorus, Inc. (NASDAQ:ONCR) insider upped their stake in the previous year

Insiders were net buyers of Oncorus, Inc.'s ( NASDAQ:ONCR ) stock during the past year. That is, insiders bought more...

Yahoo | November 29, 2021

Oncorus to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming virtual investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference: A corporate presentation will be available on-demand starting Monday, November 22nd at 10:00 a.m

Yahoo | November 23, 2021

Read More 'ONCR' Stories Here

ONCR Price Returns

1-mo N/A
3-mo -50.76%
6-mo -78.14%
1-year -91.37%
3-year N/A
5-year N/A
YTD -75.52%
2021 -83.70%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7528 seconds.